KAI Pharmaceuticals

Latest Headlines

Latest Headlines

UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout

In the latest in a string of biotech acquisitions, Amgen says it is buying KAI Pharmaceuticals for $315 million in cash.

KAI banks $13M in development deal with Japan's Ono

South San Francisco-based KAI Pharmaceuticals has inked a Japanese development and marketing deal for its lead therapy, nabbing a $13 million upfront payment from Ono Pharmaceutical. Now nearing the

BMS inks $227M collaboration deal with KAI

South San Francisco-based KAI Pharmaceuticals is getting a $25 million boost from Bristol-Myers Squibb---its upfront payment for a collaboration on KAI-9803, an experimental therapy to reduce the